Dose finding and safety analysis of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients (pts)

被引：0
|
作者：
Medioni, J. [1 ]
Deplanque, G. [2 ]
Maurina, T. [3 ]
Ferrero, J. M. [4 ]
Rodier, J. M. [5 ]
Raymond, E. [5 ]
Allyon, J. [1 ]
Kalla, S. [2 ]
Dufour-Lamartinie, J. F. [6 ]
Oudard, S. [1 ]
机构：
[1] Hop Europeen Georges Pompidou, Paris, France
[2] Ctr Hosp St Joseph, Paris, France
[3] Ctr Hosp Univ Jean Minjoz, Besancon, France
[4] Ctr Antoine Lacassagne, F-06054 Nice, France
[5] Hop Beaujon, Clichy, France
[6] Hybrigenics, Oncol, Paris, France
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71408-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：415 / 415
页数：1
相关论文
共 50 条
  • [31] Prognostic role of chromogranin a expression for docetaxel response in metastatic hormone-refractory prostate cancer (HRPC)
    Gernone, Angela
    Trabucco, Senia
    Pagliarulo, Vincenzo
    Troccoli, Giuseppe
    Pagliarulo, Arcangelo
    ANNALS OF ONCOLOGY, 2007, 18 : 65 - 65
  • [32] Experience with docetaxel in hormone-refractory prostate cancer (HRPC) at three Australian cancer centers: A retrospective study
    Hovey, Elizabeth
    Gabriel, Gabriel
    George, Monika
    Shapiro, Jeremy
    Chern, Boris
    Moylan, Eugene
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2007, 3 (03) : 156 - 162
  • [33] Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells
    Tsakalozou, Eleftheria
    Eckman, Allison M.
    Bae, Younsoo
    BIOCHEMISTRY RESEARCH INTERNATIONAL, 2012, 2012
  • [34] What is the real impact of bone pain on survival of hormone-refractory prostate cancer (HRPC) patients treated with docetaxel?
    Oudard, S.
    Banu, E.
    Medioni, J.
    Dionysopoulos, D.
    Cojocarasu, O.
    Banu, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer
    Islam R. Younis
    Daniel J. George
    Terence J. McManus
    Herbert Hurwitz
    Patricia Creel
    Andrew J. Armstrong
    Jing Jie Yu
    Kristina Bacon
    Gerald Hobbs
    Cody J. Peer
    William P. Petros
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 991 - 997
  • [36] Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer
    Younis, Islam R.
    George, Daniel J.
    McManus, Terence J.
    Hurwitz, Herbert
    Creel, Patricia
    Armstrong, Andrew J.
    Yu, Jing Jie
    Bacon, Kristina
    Hobbs, Gerald
    Peer, Cody J.
    Petros, William P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) : 991 - 997
  • [37] A multicenter phase III comparison of docetaxel (D) plus prednisone (P) and mitoxantrone (MTZ) plus P in patients with hormone-refractory prostate cancer (HRPC)
    Eisenberger, MA
    De Wit, R
    Berry, W
    Bodrogi, I
    Pluzanska, A
    Chi, K
    Oudard, S
    Christine, T
    James, N
    Tannock, I
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 2S - 2S
  • [38] Phase I study of epirubicin plus docetaxel (ET) in patients (pts) with hormone refractory prostate cancer (HRPC).
    Henary, H
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 448S - 448S
  • [39] Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients
    Nakagami, Yoshihiro
    Ohori, Makoto
    Sakamoto, Noboru
    Koga, Shoji
    Hamada, Riu
    Hatano, Tadashi
    Tachibana, Masaaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (07) : 629 - 634
  • [40] Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer
    Copur, MS
    Ledakis, P
    Lynch, J
    Hauke, R
    Tarantolo, S
    Bolton, M
    Norvell, M
    Muhvic, J
    Hake, L
    Wendt, J
    SEMINARS IN ONCOLOGY, 2001, 28 (04) : 16 - 21
12345